Histone Deacetylase Inhibitor Sodium Butyrate Attenuates Gentamicin-Induced Hearing Loss in Vivo.

Jie Wang,Ye Wang,Xin Chen,Peng-zhi Zhang,Ze-tao Shi,Li-ting Wen,Jian-hua Qiu,Fu-quan Chen
DOI: https://doi.org/10.1016/j.amjoto.2014.11.003
2012-01-01
Abstract:Objective To investigate the protective effects of histone deacetylase (HDAC) inhibitor sodium butyrate (NaB) against gentamicin (GM) ototoxicity in vivo. Methods Ten guinea pigs with normal hearing response were used for this study. A small piece of gelatin sponge (0.3 mm3) was surgically placed in the round window niche in both ears. NaB (100 mg/ml, 10μl) was infused into the gelatin in the right round window, whereas artificial perilymph (10μl)was infused into the gelatin in the left round window niche as control. Three days after surgery, animals received intramuscular injection of gentamicin (200mg/kg/day) for 5 consecutive days. The threshold of Auditory Brainstem Responses (ABRs) was measured 3 days after the final GM injection. Cochlear surface preparations were made with palloidin staining to determine the num?ber of missing cochlear hair cells as a pattern of cochleogram. Results Compared to the left ear that was treated with artifi?cial perilymph, lower thresholds of ABR and less hair cell loss were seen in NaB treated ears. Conclusion NaB may allevi?ate gentamicin-induced cochlear lesions.
What problem does this paper attempt to address?